Bosch J, Lonn EM, Dagenais GR, et al. - This study was intended to present secondary analyses of stroke outcomes by stroke subtype, predictors, treatment effects in key subgroups. Researchers randomized 12,705 participants from 21 countries with vascular risk factors but without the overt cardiovascular disease to candesartan 16 mg plus hydrochlorothiazide 12.5 mg daily or placebo and to rosuvastatin 10 mg daily or placebo using a 2-by-2 factorial design. They evaluated the effect of the interventions on stroke subtypes. Rosuvastatin 10 mg daily significantly reduced the first stroke among people at intermediate cardiovascular risk but without overt cardiovascular disease. It was shown that blood pressure lowering combined with rosuvastatin reduced ischemic stroke by 59%. As per the outcomes, both therapies are safe and generally well tolerated.